Transgene expands ProBioGen partnership with new AGE1.CR.pIX cell line license

• Transgene expanded its strategic partnership with ProBioGen through an additional license for the AGE1.CR.pIX suspension cell line.
• Deal targets improved manufacturing scalability for virus-based immunotherapies, supporting higher productivity and lower-cost, more reliable production.
• AGE1.CR.pIX is a GMP-qualified continuous cell line grown in chemically defined, animal-component-free medium to support reproducible batch starts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transgene SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080130PRIMZONEFULLFEED1001261432) on September 08, 2026, and is solely responsible for the information contained therein.